Read Larry Connors' blog – Short Term Trading Strategies
"The agreement entrenches Adcock Ingram's long-standing relationship with Baxter, giving us greater access to their product pipeline and new technology," Adcock Ingram MD Jonathan Louw said.
Under the agreement, Baxter has the option to buy 50% plus one share of Adcock Ingram's hospital products division - Adcock Ingram Critical Care - between February and July 2010.
If Baxter exercises the call option and the sale takes place, Adcock Ingram will have a put option to sell its remaining stake in the business to Baxter. The soonest the deal can be concluded would be January 1 2011, subject to approval by the competition authorities.
The companies have agreed that if Baxter chooses not to exercise its call option, Baxter's exclusive agreements with Adcock Ingram will remain in place until 2023.
Baxter and Adcock Ingram's relationship dates back to the 1940s. Baxter owned 40% of Adcock Ingram Critical Care until 1986, when it sold the shares back to Adcock Ingram to comply with anti-apartheid trade sanctions.
Baxter did however continue to supply hospital products and intellectual capital to Adcock Ingram, and later entered into a series of deals with the company including licensing, distribution and raw materials supply agreements.
Tiger Brands also announced details of its plans to list Adcock Ingram on the JSE next month , a move it said would "allow it to focus on becoming a leading South African health-care company". Adcock Ingram is SA's second-largest health care firm, trailing Aspen Pharmacare, which is Africa's biggest generic drug manufacturer and the leading supplier of medicines to the state.
"The listing will enhance the strategic flexibility of Adcock so as to enable it to embark on its own strategy to grow by acquisition and internationalise the health-care business," Peter Matlare, Tiger Brands CEO, said.
Adcock Ingram will be listed with a total debt of about R250 million.
Louw said Adcock Ingram intended to expand its international footprint with acquisitions, and planned significant investments in new infrastructure. It had set aside R850m for capital projects that would expand its capacity and ensure it complied with international manufacturing standards.
In line with the government's preference for doing business with local firms with black ownership, Adcock Ingram aimed to clinch an empowerment deal within a year of listing.
"We have an invigorated management team, and we are determined to restore our reputation post the collusion issue," he said, referring to Adcock Ingram Critical Care's role in the price-fixing scandal uncovered by the competition authorities earlier this year. The group admitted it had colluded with other firms to fix the prices of intravenous drips and related products, and divide up markets between them.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
15260 Ventura Blvd., Ste. 2200
Sherman Oaks, CA 91403
© Copyright 2009 The Connors Group, Inc.
